Trial Profile
Phase III study for evaluating efficacy and safety of desensitization based on IDEC-C2B8 in living donor kidney transplantation recipients with pre-formed anti-HLA antibody and/or donor-specific antibody. Phase III study for evaluating efficacy, safety and pharmacokinetics of pre-transplant administration of FK506 or FK506E(MR4) for 7 to 28 days in living donor kidney transplantation recipients
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 14 Dec 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Tacrolimus (Primary)
- Indications Renal transplant rejection
- Focus Adverse reactions; Pharmacokinetics; Registrational; Therapeutic Use
- Sponsors Astellas Pharma; Zenyaku Kogyo
- 29 Oct 2018 New trial record